Approved indications: Sohonos is approved to reduce the volume of new heterotopic ossification (extra bone in soft tissues) in adults and in females 8 years and older and males 10 years and older with fibrodysplasia ossificans progressiva (FOP); it is not used to remove bone that has already formed.

Off‑label uses: Clinical use of palovarotene is almost entirely limited to FOP, and there are no widely accepted or well‑studied off‑label indications at this time.

Efficacy expectations: In the pivotal phase 3 program comparing treated patients with a matched natural‑history group, Sohonos reduced the annual volume of new heterotopic bone formation by roughly half, but patients could still develop new bone and the disease remains progressive.

Time course and comparison: Benefits are assessed over many months using imaging and clinical exams, with the goal of fewer or smaller flare‑ups and slower loss of mobility compared with supportive care alone; Sohonos is currently the first and only approved disease‑modifying therapy for FOP, whereas previous management relied mainly on symptom control and avoidance of trauma.

Typical dosing: For adults and patients 14 years and older, the usual chronic dose is 5 mg by mouth once daily, with a higher “flare‑up” regimen of 20 mg once daily for 4 weeks followed by 10 mg once daily for 8 weeks (a 12‑week course) when FOP flare symptoms occur, then a return to 5 mg daily.

Pediatric dosing: For females 8–13 years and males 10–13 years, daily and flare‑up doses are adjusted by body weight, with typical chronic doses from 2.5–5 mg once daily and flare‑up doses roughly 10–20 mg daily for 4 weeks, then 5–10 mg daily for 8 weeks, as specified by the prescriber.

How to take it: Sohonos capsules are taken by mouth with food, preferably at the same time each day; capsules may be swallowed whole or opened and sprinkled onto a teaspoon of soft food (such as applesauce, low‑fat yogurt, or warm oatmeal) and taken within 1 hour, and it should not be taken with grapefruit, pomelo, or juices containing these fruits.

Special dosing instructions: Daily maintenance dosing is stopped during a flare‑up dosing cycle and then restarted afterward; if side effects are significant, clinicians may lower the dose stepwise or temporarily interrupt therapy, and dosing may also be adjusted when certain interacting medicines (such as moderate CYP3A inhibitors) are necessary.

Missed dose: If a dose is missed, it should be taken as soon as remembered unless more than about 6 hours have passed, in which case the missed dose should be skipped and the next dose taken at the regular time; two doses should not be taken at once or in the same day.

Overdose: If too many capsules are taken, especially with symptoms such as severe headache, vomiting, unusual irritability, or vision changes, the person should seek urgent medical care or contact a poison control center for guidance.

Common side effects: Very common reactions include dry skin, chapped lips, itching, rash, redness, skin peeling, hair thinning or loss, dry eyes, headache, joint or muscle pain, back pain, pain in the arms or legs, nausea, swelling of the hands or feet, fatigue, and mild hypersensitivity‑type skin reactions; these often begin in the first weeks of treatment and are usually mild to moderate but may be bothersome.

Serious or rare adverse effects: Important risks include birth defects if taken during pregnancy, premature closure of growth plates in children (which can permanently affect height and limb growth), decreased bone mineral density and vertebral fractures, bone spurs or calcification of tendons/ligaments, new or worsening depression, anxiety or suicidal thoughts, and night‑vision problems that can make driving in the dark unsafe; very rarely, retinoids have been associated with benign intracranial hypertension, especially with tetracyclines.

Warnings and precautions: Sohonos is contraindicated in pregnancy, so people who can become pregnant need regular pregnancy testing and reliable contraception during treatment and for 1 month after the last dose, and breastfeeding is not recommended during treatment or for at least 1 month afterward.

Special populations and organ function: Growing children on Sohonos require close monitoring of height and skeletal maturity, and its use is not recommended in patients with severe kidney disease or with moderate or severe liver impairment; people with osteoporosis, other bone problems, or a history of mental health disorders need particularly careful monitoring.

Overall safety profile: As with other systemic retinoids, mucocutaneous dryness and teratogenicity are expected class effects, but Sohonos also carries a distinctive risk of premature epiphyseal closure in pediatric patients, so the benefit–risk balance must be evaluated individually in specialized care.

Side‑effect reporting and safety updates: Patients and caregivers should promptly report side effects to the prescribing clinician and may report them directly to the FDA MedWatch program (by phone or online) to help track safety, and can check FDA or manufacturer communications for new safety information over time.

Drug and food interactions: Strong or moderate CYP3A4 inhibitors (such as certain azole antifungals, macrolide antibiotics, or some HIV medicines) can raise Sohonos levels and should generally be avoided or may require dose reduction, while strong or moderate CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin, or St. John’s wort) can lower its levels and reduce effectiveness; grapefruit or pomelo and their juices should be avoided because they can act like CYP3A4 inhibitors.

Other medicines and supplements: High‑dose vitamin A, other oral retinoids, and Sohonos should not be used together because of the risk of excessive retinoid toxicity, and concomitant use with tetracycline antibiotics is discouraged due to the risk of benign intracranial hypertension; patients should review all prescription drugs, over‑the‑counter medicines, and herbal supplements with their clinician before starting treatment.

Alcohol and lifestyle considerations: While no specific interaction with light to moderate alcohol use is defined, heavy alcohol intake may worsen liver strain and mood changes, so limiting alcohol and avoiding other liver‑toxic exposures are prudent; patients should also protect their skin from sun exposure because retinoids can increase photosensitivity.

Conditions requiring extra caution: Use is not recommended in people with severe renal impairment or with moderate or severe hepatic impairment, and caution is needed in those with osteoporosis or other bone disorders, pre‑existing psychiatric illness, or eye problems affecting night vision.

Monitoring needs: Ongoing care typically includes regular pregnancy testing in people who can become pregnant, periodic assessment of height and skeletal maturity in growing children, imaging or bone density testing to monitor bone health (especially the spine), and clinical monitoring for mood or behavior changes and for any vision difficulties, particularly at night.

Q: What is Sohonos prescribed for?
A: Sohonos is prescribed to reduce the amount of new abnormal bone that forms in muscles and other soft tissues in people with fibrodysplasia ossificans progressiva (FOP), starting in eligible females at 8 years and males at 10 years of age.

Q: Will Sohonos remove bone that has already formed?
A: No, Sohonos does not dissolve existing heterotopic bone; it is intended to slow or reduce the formation of new abnormal bone so that flare‑ups cause less additional damage over time.

Q: How long does it take to notice benefits?
A: The medicine is used long term, and benefits are usually seen over months as fewer or smaller new areas of heterotopic bone on scans and potentially slower loss of movement, rather than as an immediate change in day‑to‑day symptoms.

Q: How should I take Sohonos if I cannot swallow capsules?
A: You may open the capsule, sprinkle the contents on a spoonful of soft food such as applesauce or low‑fat yogurt, and swallow it right away or within 1 hour if kept at room temperature and away from direct sunlight, always taking it with food.

Q: Can I take Sohonos if I am pregnant or planning pregnancy?
A: Sohonos must not be taken during pregnancy because it can cause birth defects, and anyone who can become pregnant needs effective contraception before, during, and for 1 month after treatment, with regular pregnancy tests as directed by the clinician.

Q: How does taking Sohonos affect children’s growth?
A: In growing children, Sohonos can cause premature closure of growth plates, which may permanently limit height or change limb growth, so height and bone development are monitored closely and dosing may be adjusted or stopped if concerning changes appear.

Q: What should I do if I miss a dose?
A: If you forget a dose, take it as soon as you remember unless more than about 6 hours have passed, in which case skip the missed dose and take the next one at your regular time without doubling up.

Storage: Store Sohonos capsules at room temperature (68–77°F or 20–25°C), keep them in the original carton to protect from light, and always keep the medicine out of the reach of children.

Handling and disposal: Use capsules only if they are intact and not expired, and when you no longer need the medicine or it has expired, take it to a drug take‑back program or ask a pharmacist how to dispose of it; do not flush it down the toilet or pour it down the drain unless specifically instructed.